



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Cytokine and CAM Antagonists

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Form with fields: Patient Name, Prescriber Name, HPP Member Number, Date of Birth, Patient Primary Phone, Address, City, State ZIP, Line of Business, Drug Name, Quantity, Directions, Diagnosis Code, Diagnosis.

HPP's maximum approval time is 12 months but may be less depending on the drug.

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Is this a request for renewal of therapy with the requested drug (i.e., The requested drug has been previously approved on prior authorization)? [If yes, skip to question 95.]

Yes No

Q2. Is the requested drug prescribed for the treatment of a diagnosis that is indicated in the United States Food and Drug Administration (FDA)-approved package labeling or a medically accepted indication?

Yes No

Q3. Is the patient age-appropriate according to the Food and Drug Administration (FDA)-approved package labeling, nationally recognized compendia or peer-reviewed medical literature?

Yes No

Q4. Is the requested drug prescribed by or in consultation with an appropriate specialist (e.g., gastroenterologist, dermatologist, rheumatologist, ophthalmologist, immunologist, genetic specialist, etc.)?

Yes No

Q5. Is the patient taking any other cytokine or cell adhesion molecule (CAM) antagonist?

Yes No

Q6. Have all potential drug interactions been addressed by the prescriber (such as discontinuation of the interacting drug, dose reduction of the interacting drug or counseling of the beneficiary about the risks associated with the use of both medications when they interact)?

Yes No

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party.



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Cytokine and CAM Antagonists

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

Q7. Does the patient have any contraindications to the requested drug?
Q8. Is the prescribed dose and duration of therapy consistent with the Food and Drug Administration (FDA)-approved package labeling, nationally recognized compendia or peer-reviewed medical literature?
Q9. Is the requested drug associated with an increased risk of infection according to the Food and Drug Administration (FDA)-approved package labeling?
Q10. Is the patient up to date with immunizations in accordance with Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommendations?
Q11. Is there a plan in place for receiving the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommended immunizations?
Q12. Has the patient been evaluated for active or latent tuberculosis infection documented by results of a tuberculin skin test (purified protein derivative [PPD]) or blood test (interferon-gamma release assay)?
Q13. Does the patient have active, severe and/or uncontrolled infection (as described in the Food and Drug Administration (FDA)-approved package labeling)?
Q14. Has the patient completed the hepatitis immunization series? Note: Please attach documentation.
Q15. Has the patient undergone Hepatitis B screening (sAB, sAG and cAB)? Note: Please attach documentation.
Q16. Did the screen results indicate a risk of hepatitis B virus reactivation?
Q17. Has a follow-up plan to address this risk been developed? Note: Please attach documentation of this plan.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Cytokine and CAM Antagonists

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
---------------	------------------

<p>[If yes, skip to question 19.]</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q18. Is there a plan in place to vaccinate the patient against hepatitis B? Note: Please attach documentation of this plan.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q19. Is the requested drug associated with behavioral and/or mood changes as stated in the Food and Drug Administration (FDA)-approved package labeling (e.g., Otezla, Siliq)? [If no, skip to question 22.]</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q20. Has the patient been evaluated for a history of prior suicide attempt, bipolar disorder or major depressive disorder?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q21. While taking the requested drug, will the patient be monitored for behavioral and mood changes as recommended in the Food and Drug Administration (FDA)-approved package labeling?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q22. Does the patient have a diagnosis of moderate-to-severe Crohn's disease? [If no, skip to question 25.]</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q23. Has the disease remained active despite treatment with at least one of the following: A) Corticosteroids or B) Immunomodulators in accordance with current consensus guidelines? [If yes, skip to question 80.]</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q24. Does the patient have a history of contraindication or intolerance to both of the following: A) Corticosteroids and B) Immunomodulators in accordance with current consensus guidelines? [If yes, skip to question 80.]</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q25. Does the patient have a diagnosis of Crohn's disease that is associated with one or more high-risk or poor prognostic features? [If yes, skip to question 80.]</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q26. Has the patient achieved remission with the requested drug?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Cytokine and CAM Antagonists

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
---------------	------------------

<p>Q27. Will the requested drug be used as maintenance therapy to maintain remission? [If yes, skip to question 80.]</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q28. Does the patient have a diagnosis of ulcerative colitis (UC)? [If no, skip to question 35.]</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q29. Does the patient have mild ulcerative colitis associated with multiple poor prognostic factors? [If yes, skip to question 31.]</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q30. Is the ulcerative colitis moderate-to-severe? [If no, skip to question 33.]</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q31. Does the patient have therapeutic failure with at least one of the following treatment options: A) Aminosalicylates, B) Corticosteroids or C) Immunomodulators in accordance with current consensus guidelines? [If yes, skip to question 80.]</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q32. Does the patient have a contraindication or intolerance to all of the following treatment options: A) Aminosalicylates, B) Corticosteroids or C) Immunomodulators in accordance with current consensus guidelines? [If yes, skip to question 80.]</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q33. Has the patient achieved remission with the requested drug?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q34. Will the requested drug be used as maintenance therapy to maintain remission? [If yes, skip to question 80.]</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q35. Does the patient have a diagnosis of moderately-to-severely active rheumatoid arthritis? [If no, skip to question 38.]</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q36. Does the patient have a history of therapeutic failure of a 3-month trial of a conventional non-biologic disease-modifying antirheumatic drug (DMARD) in accordance with current consensus guidelines? [If yes, skip to question 80.]</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Cytokine and CAM Antagonists

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

Q37. Does the patient have a contraindication or intolerance to conventional non-biologic disease-modifying antirheumatic drugs (DMARDs)? [If yes, skip to question 80.]
Q38. Does the patient have a diagnosis of juvenile idiopathic arthritis (JIA)? [If no, skip to question 45.]
Q39. Does the patient have a history of therapeutic failure, contraindication or intolerance to a 3-month trial of a conventional non-biologic disease-modifying antirheumatic drug (DMARD)? [If yes, skip to question 80.]
Q40. Does the patient have systemic juvenile idiopathic arthritis (JIA) with active systemic features? [If yes, skip to question 80.]
Q41. Does the patient have a diagnosis of juvenile idiopathic arthritis (JIA) that is associated with high disease activity or one or more poor prognostic features? [If yes, skip to question 80.]
Q42. Does the patient have active sacroilitis and/or enthesitis?
Q43. Does the patient have a history of therapeutic failure of a two week trial of an oral non-steroidal anti-inflammatory drug (NSAID)? [If yes, skip to question 80.]
Q44. Does the patient have a contraindication or intolerance to oral nonsteroidal anti-inflammatory drugs (NSAIDs)? [If yes, skip to question 80.]
Q45. Does the patient have a diagnosis of ankylosing spondylitis or other axial spondyloarthritis? [If no, skip to question 48.]
Q46. Does the patient have a history of therapeutic failure of a 2-week trial of continuous treatment with two different oral nonsteroidal anti-inflammatory drugs [NSAIDs] (i.e., an oral NSAID taken daily for two weeks and a different oral

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Cytokine and CAM Antagonists

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
---------------	------------------

NSAID taken daily for 2 weeks)? [If yes, skip to question 80.] <input type="checkbox"/> Yes <input type="checkbox"/> No
Q47. Does the patient have a contraindication or intolerance to oral nonsteroidal anti-inflammatory drugs (NSAIDs)? [If yes, skip to question 80.] <input type="checkbox"/> Yes <input type="checkbox"/> No
Q48. Does the patient have a diagnosis of active psoriatic arthritis? [If no, skip to question 55.] <input type="checkbox"/> Yes <input type="checkbox"/> No
Q49. Does the patient have axial disease and/or enthesitis? [If no, skip to question 51.] <input type="checkbox"/> Yes <input type="checkbox"/> No
Q50. Does the patient have history of therapeutic failure of a 2-week trial of continuous treatment with two different oral non-steroidal anti-inflammatory drugs (NSAIDs) or a contraindication or intolerance to oral NSAIDs? [If yes, skip to question 80.] <input type="checkbox"/> Yes <input type="checkbox"/> No
Q51. Does the patient have peripheral disease? [If no, skip to question 53.] <input type="checkbox"/> Yes <input type="checkbox"/> No
Q52. Does the patient have history of therapeutic failure of an eight week trial of a conventional non-biologic disease-modifying anti-inflammatory drug (DMARD), or a contraindication or intolerance to conventional non-biologic DMARDs? [If yes, skip to question 80.] <input type="checkbox"/> Yes <input type="checkbox"/> No
Q53. Does the patient have severe disease as determined by the prescriber? [If yes, skip to question 80.] <input type="checkbox"/> Yes <input type="checkbox"/> No
Q54. Does the patient have concomitant moderate-to-severe nail disease? [If yes, skip to question 80.] <input type="checkbox"/> Yes <input type="checkbox"/> No
Q55. Does the patient have a diagnosis or moderate-to-severe chronic psoriasis? [If no, skip to question 60.]

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Cytokine and CAM Antagonists

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
---------------	------------------

Yes No

Q56. Does the patient have psoriasis associated with at least one of the following: A) A body surface area (BSA) of 3 percent or more that is affected, B) A BSA of less than 3 percent that is affected with involvement of critical areas, C) Significant disability or impairment of physical or mental functioning?

Yes No

Q57. Does the patient have history of therapeutic failure of topical corticosteroids or other topical pharmacologic therapy?
[If yes, skip to question 59.]

Yes No

Q58. Does the patient have a contraindication or intolerance to topical corticosteroids and other topical pharmacologic therapy?

Yes No

Q59. Does the patient have a history of one or more of the following: A) Therapeutic failure of a 3-month trial of oral systemic therapy, B) Therapeutic failure of ultraviolet light therapy or C) A contraindication or intolerance to oral systemic therapies and ultraviolet light therapy?
[If yes, skip to question 80.]

Yes No

Q60. Does the patient have a diagnosis of moderate-to-severe hidradenitis suppurativa?
[If no, skip to question 63.]

Yes No

Q61. Does the patient have Hurley stage II or stage III disease?

Yes No

Q62. Does the patient have a history of therapeutic failure, contraindication or intolerance to both of the following: A) A three month trial of topical clindamycin, B) An adequate trial of systemic antibiotics?
[If yes, skip to question 80.]

Yes No

Q63. Does the patient have a diagnosis of non-infectious uveitis?
[If no, skip to question 68.]

Yes No

Q64. Is the diagnosis of uveitis associated with juvenile idiopathic arthritis (JIA) or Behcet's syndrome?
[If yes, skip to question 80.]

Yes No

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Cytokine and CAM Antagonists

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

Q65. Does the patient have a history of therapeutic failure, contraindication or intolerance to one of the following: A) Systemic, topical, intraocular or periocular corticosteroids or B) Conventional systemic immunosuppressives? [If yes, skip to question 80.]

Yes No

Q66. Does the patient have corticosteroid-dependent uveitis?

Yes No

Q67. Will the requested drug be used with the intent of discontinuing or decreasing the dose of the systemic corticosteroid? [If yes, skip to question 80.]

Yes No

Q68. Does the patient have a diagnosis of giant cell arteritis? [If no, skip to question 73.]

Yes No

Q69. Does the patient have history of therapeutic failure, contraindication or intolerance to systemic glucocorticoids? [If yes, skip to question 80.]

Yes No

Q70. Is the patient at high-risk for glucocorticoid-related complications? [If yes, skip to question 80.]

Yes No

Q71. Does the patient have glucocorticoid-dependent disease?

Yes No

Q72. Will the requested drug be used with the intent of discontinuing or decreasing the dose of the systemic glucocorticoid? [If yes, skip to question 80.]

Yes No

Q73. Does the patient have a diagnosis of familial Mediterranean fever? [If no, skip to question 75.]

Yes No

Q74. Does the patient have a history of therapeutic failure of at least a three month trial with colchicine at maximally tolerated doses or a contraindication or intolerance to colchicine?

Yes No



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Cytokine and CAM Antagonists

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

Q75. Does the patient have a diagnosis of Behcet's syndrome?
Q76. Has the diagnosis of Behcet's syndrome been confirmed by current consensus guidelines?
Q77. Does the patient have recurrent ulcers associated with Behcet's syndrome?
Q78. Does the patient have a history of therapeutic failure with, contraindication or intolerance to a topical corticosteroid (e.g., triamcinolone dental paste)?
Q79. Does the patient have a history of one of the following: A) Therapeutic failure of an adequate trial of colchicine at maximally tolerated doses or B) A contraindication or intolerance to colchicine?
Q80. Is the request for Cosentyx (secukinumab)? [If no, skip to question 83.]
Q81. Does the patient have a history of therapeutic failure, contraindication or intolerance of Humira (adalimumab) if approved or medically accepted for the beneficiary's diagnosis? [If yes, skip to question 92.]
Q82. Does the patient have a current history of (within the past 90 days) of being prescribed Cosentyx (secukinumab)? [If yes, skip to question 92.]
Q83. Is the request for Arcalyst (rilonacept)? [If no, skip to question 86.]
Q84. Does the patient have a history of therapeutic failure, contraindication or intolerance of Kineret (anakinra) if approved or medically accepted for the beneficiary's diagnosis? [If yes, skip to question 92.]
Q85. Does the patient have a current history of (within the past 90 days) of being prescribed Arcalyst (rilonacept)? [If yes, skip to question 92.]

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Cytokine and CAM Antagonists

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
---------------	------------------

<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q86. Is the request for Ilaris (canakinumab)? [If no, skip to question 89.]	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q87. Does the patient have a history of therapeutic failure, contraindication or intolerance to Kineret (anakinra) if approved or medically accepted for the patient's diagnosis? [If yes, skip to question 92.]	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q88. Does the patient have a current history of (within the past 90 days) of being prescribed Ilaris (canakinumab)? [If yes, skip to question 92.]	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q89. Is this request for an infliximab product other than Renflexis (infliximab-abda)?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q90. Does the patient have history of therapeutic failure, contraindication or intolerance of Renflexis (infliximab-abda) if approved or medically accepted for the diagnosis? [If yes, skip to question 92.]	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q91. Does the patient have a current history of (within the past 90 days) of being prescribed infliximab?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q92. Is the request for a non-preferred cytokine or cell adhesion molecule (CAM) antagonist?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q93. Does the patient have a history of therapeutic failure, contraindication or intolerance to the preferred cytokine or cell adhesion molecule (CAM) antagonists approved or medically accepted for the diagnosis?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q94. Has the patient been prescribed the same non-preferred cytokine or cell adhesion molecule (CAM) antagonist within the past 90 days?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q95. Has the patient experienced improvement in disease activity and/or level of functioning since initiating therapy with the requested cytokine and cell adhesion molecule (CAM) antagonist?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Cytokine and CAM Antagonists

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
---------------	------------------

<p>Q96. Is the requested drug prescribed by or in consultation with an appropriate specialist (e.g., gastroenterologist, dermatologist, rheumatologist, ophthalmologist, immunologist, genetic specialist, etc.)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q97. Is the prescribed dose and duration of therapy consistent with the Food and Drug Administration (FDA)-approved package labeling, nationally recognized compendia or peer-reviewed medical literature?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q98. Have all potential drug interactions been addressed by the prescriber (such as discontinuation of the interacting drug, dose reduction of the interacting drug or counseling of the beneficiary about the risks associated with the use of both medications when they interact)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q99. Is the patient currently taking any other cytokine or cell adhesion molecule (CAM) antagonist?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q100. Is the requested drug associated with behavioral and/or mood changes as stated in the Food and Drug Administration (FDA)-approved package labeling?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q101. Has the patient been evaluated for behavioral and mood changes as recommended in the Food and Drug Administration (FDA)-approved package labeling?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q102. Additional Information:</p>

Prescriber Signature

Date

Updated for 2020